CareDx, Inc. (NASDAQ:CDNA) will be hosting a conference call at 4:30 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.caredxinc.com
Earnings Expectation
CareDx, Inc. is expected to report third quarter earnings results, after market close, on Thursday 29th October 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.06 per share from revenue of $ 53.01 million. Looking ahead, the full year loss are expected at $ 0.11 per share on the revenues of $ 184.30 million.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 53.00 million ~ $ 53.00 million
Full Year 2020 topline are forecasted in a range of$ 165.00 million ~ $ 168.00 million
Click Here For More Historical Outlooks Of CareDx, Inc.
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide. The company develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell-free DNA test initially used for kidney transplant patients.
